Last reviewed · How we verify
NCT04056221
Effects of Acupuncture on Sjögren's Syndrome
NA trial testing Acupuncture in Sjogren's Syndrome in 50 participants. Completed in 10 October 2022.
6 December 2021
Quick facts
| Lead sponsor | Ana Carolina Fragoso Motta, DDS, PhD |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 18 February 2019 |
| Primary completion | 6 December 2021 |
| Estimated completion | 10 October 2022 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Acupuncture — full drug profile →
- Sham acupuncture
Conditions studied
- Sjogren's Syndrome — all drugs for Sjogren's Syndrome →
Sponsor
Ana Carolina Fragoso Motta, DDS, PhD
Who can join
18 and older, any sex, with Sjogren's Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sjögren's syndrome (SS) is a multisystemic chronic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands, resulting in salivary and lacrimal glands hypofunction, with symptoms of dry eyes and mouth. Xerostomia and xerophthalmia present profound negative impact on patients' quality of life, especially due to difficulties in swallowing, dysarthria, dysgeusia, halitosis and burning tongue, discomfort and visual disturbances that lead to daily activities difficulty such as driving or reading. Although some drugs may improve symptoms and prevent SS complications, they can cause significant adverse effects and even fail to relieve symptoms. Integrative and complementary techniques have become a therapeutic option for SS patients. Scientific evidence has supported the efficacy of acupuncture in relieving symptoms of xerostomia and xerophthalmia. Due to the lack of well-controlled and standardized clinical studies, this study aimed to conduct a randomized and controlled trial to determine the efficacy of acupuncture as a therapeutic option for SS patients' symptoms relief.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Dry eye syndrome: comprehensive etiologies and recent clinical trials.
Huang R, Su C, Fang L, Lu J, et al · · 2022 · cited 52× · PMID 35678897 · DOI 10.1007/s10792-022-02320-7 -
Understanding Fatigue in Sjögren's Syndrome: Outcome Measures, Biomarkers and Possible Interventions.
Mæland E, Miyamoto ST, Hammenfors D, Valim V, et al · · 2021 · cited 25× · PMID 34249008 · DOI 10.3389/fimmu.2021.703079 -
Prospective Sham-Controlled trial: acupuncture for symptom-relieving in patients with Sjögren's disease.
Gomes-Silva JM, Torres CP, Teixeira LR, Saraiva MDCP, et al · · 2025 · PMID 40178679 · DOI 10.1007/s10067-025-07410-2
Verify or expand the search:
- PubMed search for NCT04056221
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Acupuncture
Trials testing the same drug.
- NCT07522567 — Efficacy of Acupuncture on Chronic Tinnitus and Its Association With Auditory Brainstem Response Measures · NA · not yet recruiting
- NCT07575334 — Acupuncture Therapy for Sudden Sensorineural Hearing Loss · NA · recruiting
- NCT07522710 — Clinical Study on Intensive Multi-acupuncture in the Treatment of Neck and Shoulder Myofascial Pain Syndrome · NA · not yet recruiting
- NCT07505927 — Acupuncture for Postoperative Gastric Emptying Delay · NA · not yet recruiting
- NCT07410793 — Acupuncture With Chinese Herbal Cream Compare With Acupuncture With Calcipotriol in Plaque Psoriasis. · Phase 2 · recruiting
Other recruiting trials for Sjogren's Syndrome
Currently open trials in the same condition.
- NCT07281456 — Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease · Phase 2 · recruiting
- NCT07180537 — Creating Health Course Study for People With Rheumatological Conditions · NA · recruiting
- NCT07236762 — An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases · Phase 1 · recruiting
- NCT07041099 — A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease · Phase 1 · recruiting
- NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04056221 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ana Carolina Fragoso Motta, DDS, PhD
- Last refreshed: 14 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04056221.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing